The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
By-passing in vitro screening—next generation sequencing technologies applied to antibody display and in silico candidate selection
Open accessAbstract
In recent years, unprecedented DNA sequencing capacity provided by next generation sequencing (NGS) has revolutionized genomic research. Combining the Illumina sequencing platform and a scFv library designed to confine diversity to both CDR3, >1.9 × 10(7) sequences have been generated. This approach allowed for in depth analysis of the library's diversity, provided sequence information on virtually all scFv during selection for binding to two targets and a global view of these enrichment processes. Using the most frequent heavy chain CDR3 sequences, primers were designed to rescue scFv from the third selection round. Identification, based on sequence frequency, retrieved the most potent scFv and valuable candidates that were missed using classical in vitro screening. Thus, by combining NGS with display technologies, laborious and time consuming upfront screening can be by-passed or complemented and valuable insights into the selection process can be obtained to improve library design and understanding of antibody repertoires.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sequencing technologies – the next generation
Metzker, M. L. (2010) · Nature Reviews Genetics · doi:10.1038/nrg2626 · Cited by 7,066
de Kruif, J., Boel, E., & Logtenberg, T. (1995) · Journal of Molecular Biology · doi:10.1006/jmbi.1995.0204 · Cited by 173
Cited by
The promise and challenge of high-throughput sequencing of the antibody repertoire
Georgiou, G., Ippolito, G. C., Beausang, J., Busse, C. E., Wardemann, H., & Quake, S. R. (2014) · Nature Biotechnology · doi:10.1038/nbt.2782 · Cited by 652
Nanobodies and Their Potential Applications
Hassanzadeh-Ghassabeh, G., Devoogdt, N., De Pauw, P., Vincke, C., & Muyldermans, S. (2013) · Nanomedicine · doi:10.2217/nnm.13.86 · Cited by 328
Aptamer Selection Technology and Recent Advances
Blind, M., & Blank, M. (2015) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2014.74 · Cited by 322
The state-of-play and future of antibody therapeutics
Elgundi, Z., Reslan, M., Cruz, E., Sifniotis, V., & Kayser, V. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.11.004 · Cited by 322
Alam, K. K., Chang, J. L., & Burke, D. H. (2015) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2015.4 · Cited by 260
Metadata
- Authors
- Ravn, U., Gueneau, F., Baerlocher, L., Osteras, M., Desmurs, M., Malinge, P., Magistrelli, G., Farinelli, L., Kosco-Vilbois, M. H., & Fischer, N.
- Venue
- Nucleic Acids Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2010-09-15
- Volume
- 38
- Issue
- 21
- Pages
- e193-e193
- ISSN
- 0305-1048 (ISSN-L)
- 1362-4962
- OpenAlex
- W2116006352
- Cited by
- 173
- References
- 2
- FWCI
- 10.37
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: By-passing in vitro screening—next generation sequencing technologies applied to antibody display and in silico candidate selection. https://app.cochat.ai/papers/10.1093/nar/gkq789
- The paper
- Ravn, U., Gueneau, F., Baerlocher, L., Osteras, M., Desmurs, M., Malinge, P., Magistrelli, G., Farinelli, L., Kosco-Vilbois, M. H., & Fischer, N. (2010). By-passing in vitro screening—next generation sequencing technologies applied to antibody display and in silico candidate selection. Nucleic Acids Research. https://doi.org/10.1093/nar/gkq789
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.